C4 Therapeutics is a clinical-stage biopharmaceutical company focused on targeted protein degradation: small molecules that tag disease-causing proteins for the cell’s natural recycling machinery. Its proprietary TORPEDO platform designs both heterobifunctional (BiDAC) and molecular-glue (MonoDAC) degraders, as well as payloads for degrader-antibody conjugates. Programs center on oncology and other hard-to-treat diseases, including collaborations that apply the platform to external targets.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 6.5 | — | -26 | — |
| Q3 2025 | 11.2 | — | -32.2 | — |
| Q4 2025 | 11 | — | -20.5 | — |
| Q1 2026 | 6.2 | — | -25.1 | — |
| Q2 2026 | 6.6 | 2.8% | -23.6 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: BayCom Corp (BCML), Avidbank Holdings, Inc. (AVBH), Collective Acquisition Corp. II (CAII), Energy Recovery, Inc. (ERII), Praetorian Acquisition Corp. (PTOR), Inflection Point Acquisition Corp. VI (IPFX)